Significance of the gleason scoring system after neoadjuvant hormonal therapy

G. Bentley, J. Dey, W. A. Sakr, D. P. Wood, J. E. Pontes, D. J. Grignon

Research output: Contribution to journalArticle

16 Scopus citations


Neoadjuvant hormonal therapy (NHT) induces morphologic changes in prostate adenocarcinoma that result in the assignment of higher Gleason scores on average than in pretreatment biopsy specimens. This outcome has led to the recommendation that the Gleason scoring system not be applied to prostate adenocarcinoma specimens after NHT. We reviewed the radical prostatectomy specimens of 116 patients who had received NHT. Gleason scores were assigned on the post-treatment specimens by applying the usual criteria; in addition, an estimated pretreatment Gleason score was assigned on the basis of knowledge of the morphologic alterations associated with NHT. Finally, an estimate of the degree of therapy effect was assigned: little or no evidence of hormonal effect (grade 1) to marked therapy-related changes (grade 3). Both the post-treatment and the estimated pretreatment Gleason score correlated significantly with biochemical progression (P = 0.03 and P = 0.03, respectively; log-rank test). The degree of therapy effect did not correlate with progression (P = 0.46; log-rank test). This limited analysis suggests that despite the morphologic alterations induced by NHT, post-treatment Gleason score remains a significant prognostic measure. Further studies in more uniformly treated populations are required to confirm this observation.

Original languageEnglish (US)
Pages (from-to)125-129+131
JournalMolecular Urology
Issue number3
StatePublished - Nov 13 2000

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Significance of the gleason scoring system after neoadjuvant hormonal therapy'. Together they form a unique fingerprint.

  • Cite this

    Bentley, G., Dey, J., Sakr, W. A., Wood, D. P., Pontes, J. E., & Grignon, D. J. (2000). Significance of the gleason scoring system after neoadjuvant hormonal therapy. Molecular Urology, 4(3), 125-129+131.